ARTICLE | Emerging Company Profile

Prolysis: A fresh look at antibiotics

August 30, 2004 7:00 AM UTC

The degree of bacterial resistance against existing antibiotics has become a major public health threat. However, obstacles to the development of new antibiotics are considerable: some of the new targets have proven to be intractable, good animal models only exist for a limited set of infections, clinical trials are complicated, and compounds often must be tested in comparison with existing antibiotics.

Prolysis Ltd. believes it can overcome some of the earlier-stage hurdles with its whole cell assay technology, which identifies compounds that target essential bacterial processes...